

UMass Chan Medical School

eScholarship@UMassChan

University of Massachusetts Medical School Faculty Publications

2021-05-13

Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-Acquired Pneumonia in Hospitalized US Adults

Raul Isturiz
Pfizer Inc

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs



Part of the [Bacterial Infections and Mycoses Commons](#), [Biological Factors Commons](#), [Emergency Medicine Commons](#), [Immunoprophylaxis and Therapy Commons](#), [Infectious Disease Commons](#), and the [Respiratory Tract Diseases Commons](#)

Repository Citation

Isturiz R, Volturo GA. (2021). Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-Acquired Pneumonia in Hospitalized US Adults. University of Massachusetts Medical School Faculty Publications. <https://doi.org/10.1093/cid/ciab375>. Retrieved from https://escholarship.umassmed.edu/faculty_pubs/2047

Creative Commons License



This work is licensed under a [Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 License](#). This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in University of Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.

Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-Acquired Pneumonia in Hospitalized US Adults

Raul Isturiz,^{1*} Lindsay Grant,¹ Sharon Gray,¹ Ronika Alexander-Parrish,¹ Qin Jiang,¹ Luis Jodar,¹ Paula Peyrani,¹ Kimbal D. Ford,¹ Michael W. Pride,² Wesley H. Self,³ Francis Counselman,⁴ Gregory Volturo,⁵ Luis Ostrosky-Zeichner,⁶ Richard G. Wunderink,⁷ Robert Sherwin,⁸ J. Scott Overcash,⁹ Thomas File,¹⁰ Julio Ramirez¹¹

¹Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA; ²Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA; ³Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; ⁴Department of Emergency Medicine, Eastern Virginia Medical School, Norfolk, VA, USA; ⁵Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, USA; ⁶McGovern Medical School and Memorial Hermann Medical Center, Houston, TX, USA; ⁷Department of Medicine, Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ⁸Department of Emergency Medicine, Wayne State University, Detroit, MI, USA; ⁹eStudySite Clinical Research, Chula Vista, CA, USA; ¹⁰Summa Health, Northeast Ohio Medical University, Akron, OH, USA; ¹¹Division of Infectious Diseases, University of Louisville, Louisville, KY, USA

***Corresponding author:** Raul Isturiz
Pfizer Inc
500 Arcola Road
Collegeville, PA 19426 USA
Tel: 484-865-9535
Fax: 484-865-6415
Email: raul.isturiz@pfizer.com

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Summary: A novel urinary antigen detection assay substantially increased detection of non-PCV13 serotypes included in an investigational 20-valent pneumococcal conjugate vaccine (PCV20) among US adults with community-acquired pneumonia (CAP). PCV20 may address the burden of CAP due to the additional serotypes.

Accepted Manuscript

Abstract

Background: *Streptococcus pneumoniae* is a causative agent of community-acquired pneumonia (CAP). The 13-valent pneumococcal conjugate vaccine (PCV13) has significantly decreased the burden of PCV13-serotype pneumococcal disease; however, disease due to nonvaccine serotypes remains substantial. A recent study documented the persistence of PCV13 serotypes among US adults hospitalized with radiographically confirmed CAP. The current analysis used a recently developed urinary antigen detection (UAD) assay (UAD2) to extend these results to additional serotypes included in an investigational PCV20 vaccine.

Methods: This prospective study enrolled adults aged ≥ 18 years hospitalized with radiographically confirmed CAP between October 2013–September 2016. Presence of *S pneumoniae* was determined by blood and respiratory sample culture, BinaxNOW[®] urine testing, and UAD. In addition to Quellung on cultured isolates when available, serotypes were identified from urine specimens using UAD1 for PCV13 serotypes and UAD2 for 7 PCV20-unique serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) and 4 additional serotypes (2, 9N, 17F, and 20).

Results: Among 12,055 subjects with radiographically confirmed CAP, 1482 were positive for *S pneumoniae*. PCV13 and PCV20-unique serotypes were associated with 37.7% (n=559) and 27.0% (n=400) of cases, respectively; 288 subjects were exclusively diagnosed as positive for *S pneumoniae* by UAD2. Demographic and clinical disease characteristics were similar between subjects with CAP caused by PCV13 and PCV20-unique serotypes.

Conclusions: The current analysis using UAD2 identified a sizeable proportion of hospitalized adult CAP associated with PCV20-unique serotypes. PCV20 may therefore address the burden of CAP caused by the additional serotypes present in the vaccine.

Keywords: pneumonia, urinary antigen detection, adult, 20-valent pneumococcal conjugate vaccine, serotypes

Introduction

Community-acquired pneumonia (CAP) is a common cause of morbidity and mortality in the United States and globally [1, 2]. In the United States, the burden of CAP is particularly pronounced among individuals ≥ 65 years old, for whom a recent study of CAP requiring hospitalization yielded an incidence rate of 2093 cases per 100,000 population [1]. Hospitalization rates for CAP in the same study correlated with increasing age, with 898, 1507, 2205, and 3951 hospitalizations per 100,000 population for those 60 to 64, 65 to 74, 75 to 84, and ≥ 85 years of age, respectively; all-cause mortality rates were 6.5% during CAP hospitalization and 30.6% within one year.

Vaccines are available to prevent CAP caused by *Streptococcus pneumoniae*, which contributes to 10% to 14% of confirmed US adult hospitalized CAP cases [3, 4] and is thus a significant component of CAP burden. The 13-valent pneumococcal conjugate vaccine (PCV13) is licensed for active immunization for the prevention of invasive disease caused by pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F [5].

The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) has recommended PCV13 use in all children < 5 years old since 2010 [6]; this recommendation led to substantial declines in PCV13-serotype pneumococcal disease via both direct effects in the vaccinated pediatric population and indirect effects in other age groups [7]. Point estimates of PCV13 vaccine efficacy against nonbacteremic PCV13-serotype CAP was 45.0% in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPITA); a real-world evaluation estimated vaccine effectiveness of PCV13 to be 70.1% [11, 12]. However, the burden of non-PCV13 serotype disease remains substantial, representing 42% and 75% of invasive pneumococcal disease (IPD) cases in children and adults, respectively [13, 14]. Additionally, a substantial proportion of CAP is attributed to non-PCV13 serotypes [3]. Higher-valent pneumococcal conjugate vaccines (PCVs, including a 15-valent PCV [PCV15; containing serotypes in PCV13 as well as 22F and 33F] and a 20-valent PCV [PCV20; containing serotypes in PCV15 as well as 8, 10A, 11A, 12F, and 15B]) targeting some of these serotypes are currently in development and have been evaluated in adults [15, 16].

Laboratory methods are critical for assessing serotype-specific etiology of pneumococcal CAP and thus potential coverage by existing and investigational vaccines. The very small proportion of respiratory cultures available in nonbacteremic pneumococcal pneumonia cases mandates an alternative approach to determine causative serotypes [17, 18]. A urinary antigen detection (UAD)

assay, termed UAD1, was previously developed for the detection of the PCV13 serotypes (ie, 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in urine samples from patients with CAP [19]. The assay was validated against urine specimens from patients with bacteremic CAP but has the added advantage of evaluating PCV13 serotypes in nonbacteremic CAP [19]. UAD assays can thus help monitor CAP epidemiology and support vaccine efficacy evaluations as was done in a large study assessing PCV13 efficacy against CAP in 84,496 older adults [19, 20]. A recent observational, prospective surveillance study used the UAD1 assay to document the persistence of PCV13 serotypes among US adults hospitalized with radiographically confirmed CAP [3].

A second UAD assay, termed UAD2, has been developed for the identification of 11 additional pneumococcal serotypes beyond those evaluated by UAD1 [21]; these 11 serotypes include the 7 non-PCV13 serotypes covered by the investigational PCV20 vaccine (8, 10A, 11A, 12F, 15B, 22F, and 33F) [15] and an additional 4 serotypes (2, 9N, 17F, and 20). Collectively, UAD1 and UAD2 detect 24 pneumococcal serotypes [21]. The current analysis used UAD2 to extend the previously published study findings regarding the percentage of PCV13-serotype CAP among radiographically confirmed US adult CAP cases, as evaluated by UAD1 [3], to those serotypes included in UAD2.

Methods

Study Design and Participants

The study design and associated methodologies have been previously reported [3, 22]. Briefly, this prospective, multicenter surveillance study enrolled adults ≥ 18 years old hospitalized with radiographically confirmed CAP in 10 US cities between October 2013 and September 2016. For inclusion, subjects had to present with suspected CAP based on 2 or more predefined signs or symptoms, have a radiographic finding consistent with pneumonia within 72 hours before study enrollment, be able and willing to provide a urine sample, and provide informed consent. Subjects with hospital-acquired pneumonia (ie, hospitalized for ≥ 48 hours before development of symptoms or transfer to study site), who had received a pneumococcal vaccine within 30 days before enrollment, or who had enrolled in the study within the previous 30 days were excluded, as were subjects with severe chronic conditions or laboratory/radiographic abnormalities that could interfere with interpretation of study results, as judged by the investigator.

Subjects were classified as high-risk (ie, immunocompromised) if they had chronic kidney disease, organ transplantation, immunodeficiency, hematologic or solid tumor malignancy, AIDS, HIV, or were treated with immunosuppressive drug therapy. At-risk subjects were those without immunocompromising conditions who had asthma, congestive heart failure, liver disease, chronic obstructive pulmonary disease, diabetes mellitus, or alcohol abuse or who were currently smoking. All other subjects were classified as low-risk.

Study Procedures and Assessments

Demographic information, medical history, and clinical data of consented participants were collected. Microbiologic results were recorded from blood and respiratory cultures (eg, high-quality sputum, bronchoalveolar lavage, pleural fluid, tracheal aspirate). Urine samples were collected from all participants, preferably within 24 hours of enrollment.

Blood and respiratory samples were cultured and underwent antimicrobial susceptibility testing in local laboratories according to local laboratory standard methods. Samples positive for *S pneumoniae* were sub-cultured at the study site and shipped at ambient temperature to the German National Reference Center for Streptococci at Aachen University for confirmatory testing. *S. pneumoniae* were recultured on sheep blood agar plates and assessed for optochin sensitivity and bile solubility. If further confirmation was required, 16s rRNA and *sodA* sequencing were performed. Serotyping was performed by Neufeld Quellung reaction using anti-sera obtained from the Statens Serum Institute in Copenhagen, Denmark.

Urine specimens were tested by BinaxNOW™ (a commercially available testing kit for the identification of *S pneumoniae*; Abbott Diagnostics Scarborough Inc., Scarborough, ME, USA), UAD1, and UAD2 at Pfizer's Vaccines Research and Development Laboratory (Pearl River, NY, USA) [19, 21]. The UAD assay is a limit assay that uses Luminex technology, with positivity cutoff limits (based on antigen concentrations read off a standard curve), established for each serotype using 400 control urine specimens collected from otherwise healthy adults without CAP. Using nonparametric tolerance intervals the assay is set to achieve at least 97% specificity for each serotype. The UAD1 assay is designed to capture 13 *S pneumoniae* serotype-specific polysaccharides excreted in human urine, and the UAD2 assay is able to detect an additional 11 *S pneumoniae* serotypes.

Data Analysis

Subjects were considered positive for *S pneumoniae* if they had at least one positive pneumococcal test result from culture (from blood, high-quality sputum, bronchoalveolar lavage, pleural fluid, tracheal aspirate, or other specimen type), BinaxNOW, UAD1, or UAD2. The 24 UAD1/UAD2 serotypes, as determined from cultured isolates and UAD assays, were categorized into different groups for analysis including PCV13 serotypes, PCV20 serotypes, PCV20-unique serotypes (ie, serotypes included in PCV20 but not PCV13 [8, 10A, 11A, 12F, 15B, 22F, 33F]), and non-PCV20 serotypes. Percentages of subjects with radiographically confirmed CAP were analyzed descriptively within these groups and for individual serotypes. Subjects positive for multiple serotypes were included within the total for each corresponding serotype and could therefore be included in multiple groups.

Results

As detailed in the publication describing UAD1 results, of the 15,572 participants enrolled in the study, 12,055 had radiographically confirmed CAP and were included in the final analysis

population; subjects without radiographically confirmed CAP were excluded from the final analysis [3]. Approximately half of the patients were female, and most were white/non-Hispanic. Slightly more than half (n=6347; 52.7%) were ≥65 years old; of these, 43.7% were high-risk, 43.8% were at-risk, and 12.5% were low-risk. Among the 5708 subjects aged 18 to 64 years, 32.7% were high-risk, 52.1% were at-risk, and 15.2% were low-risk.

Among the 12,055 subjects with radiographically confirmed CAP, 12.3% (n=1482) had a positive result for *S pneumoniae* as determined by culture, BinaxNOW, UAD1, and/or UAD2; 722 (48.7%) of these subjects were ≥65 years of age, and 760 (51.3%) were 18 to 64 years of age. *S pneumoniae* was detected by UAD1 and/or UAD2 in 69.4% (n=1028) of these subjects, including 42.7% of subjects (n=633) in whom *S pneumoniae* was not detected by any other method (**Figure 1**). A total of 288 subjects were exclusively diagnosed as positive for *S pneumoniae* by UAD2. For the remainder of subjects, *S pneumoniae* was detected by BinaxNOW alone (n=348; 23.5%), culture alone (n=68; 4.6%), or both BinaxNOW and culture (n=38; 2.6%).

Among 1134 subjects positive for *S pneumoniae* by culture, UAD1, or UAD2, 1111 (9.2% of the 12,055 total cases) had serotyping information available. Among these, 559 (4.6%) were positive for the UAD1 serotypes, 516 (4.3%) for the additional UAD2 serotypes, 1001 (8.3%) for the serotypes collectively included in UAD1 and UAD2, and 64 (0.5%) for the non-UAD1/UAD2 serotypes. Of the 1001 subjects positive for UAD1 and/or UAD2 serotypes combined, 74 subjects were positive for both UAD1 and UAD2 serotypes. The serotype distribution by age and risk group among subjects with UAD1/UAD2 serotypes identified is shown in **Table 1**. Overall, percentages of subjects with radiographically confirmed CAP caused by PCV13 or PCV20-unique serotypes were slightly higher in the younger age group regardless of risk status. The current analysis identified 400 subjects (3.3%) with radiographically confirmed CAP caused by the 7 PCV20-unique serotypes. Among PCV20-unique serotypes, serotype 22F was associated with the highest number of cases (n=126; 1.1%), followed by serotype 11A (n=97; 0.8%). The non-PCV20 serotypes included in UAD2 were collectively associated with 123 (1.0%) cases, with serotype 9N responsible for approximately half of these cases (n=60; 0.5%).

The demographics, risk status, and disease characteristics of subjects with radiographically confirmed CAP caused by PCV13 and PCV20-unique serotypes are shown in **Table 2**. Demographic information for both groups were similar to those described above for the overall population of subjects with radiographically confirmed CAP. In both groups, approximately one-third of subjects had ≥ 2 at-risk conditions. Clinical characteristics were similar between the two groups; these included mean Pneumonia Severity Index (PSI; PCV13 serotypes: 90.7; PCV20-unique serotypes: 85.9), most frequent PSI grade (IV; PCV13 serotypes: 32.4%; PCV20-unique serotypes: 30.3%), and mean inpatient hospitalization days (PCV13 serotypes: 6.9; PCV20-unique serotypes: 6.8), among others.

Discussion

Previously presented results from this study found that 1194 of 12,055 (9.9%) US adults hospitalized with radiographically confirmed CAP were positive for *S pneumoniae* based on culture, BinaxNOW, or UAD1 [3]. Before the use of the UAD2 assay, non-PCV13 serotypes were detected for only 173 (1.4%) of the 12,055 subjects; this underestimate resulted from culture of blood and respiratory samples being the only available method for identification of these additional serotypes [3]. The addition of 288 subjects exclusively diagnosed by UAD2 dramatically increased the number of patients with radiographically confirmed CAP positive for *S pneumoniae* to 1482 (12.3%). These findings support suggestions by others that the contribution of *S pneumoniae* to nonbacteremic CAP may be larger than indicated in previous studies that were more limited in diagnostic capability [3, 4, 18, 23]. Data on IPD from CDC Active Bacterial Core surveillance (ABCs) in 2016 found that approximately 25% to 40% of IPD cases were due to serotypes other than those detected by UAD1/UAD2 [13]. Therefore, further expanding the coverage of UAD assays beyond the 24 serotypes already included in UAD1 and UAD2 may identify an even greater proportion of CAP caused by *S pneumoniae*.

While 2.2% of CAP patients were positive for a PCV20-unique serotype using UAD2, this may be an underestimate of the true burden, as has been suggested for PCV13 serotypes identified by UAD1 [3]. A large database study of US Medicare beneficiaries ≥ 65 years of age enrolled during 2014–2017 found that PCV13 prevented 6.0% to 11.4% of all-cause CAP [24]; a similar PCV13 impact against all-cause CAP is supported by two additional studies from Europe, including an RCT (CAPiTA) [25, 26]. We found that the proportion of primarily UAD1-confirmed CAP due to PCV13 serotypes was 4.4%. Applying a PCV13 effectiveness of 50% [12, 27] to this value suggests that vaccination should prevent 2.2% of all CAP among older US adults rather than the 6% to 11.4% from the Medicare study. UAD is a tool to assess serotype distribution, and while the UAD assays are highly sensitive against bacteremic CAP [19, 21], sensitivity against non-bacteremic CAP is unknown due to lack of a gold standard; consequently, UAD1 may have substantially underestimated the true proportion of CAP due to PCV13 serotypes. Etiologically confirmed pneumococcal CAP also may underestimate the proportion of CAP preventable by PCVs because PCVs prevent pneumococcal carriage acquisition and reduce density, and pneumococcal carriage may increase the likelihood of symptomatic viral infection, including viral lower respiratory tract infections [28-30]. Lastly, estimates of PCV13 effectiveness against all-cause CAP could be biased; however, as indicated above, multiple studies from Europe and the US – including an RCT (CAPiTA) – produced similar effectiveness estimates [24-26]. While data such as these are only available for PCV13 serotypes, it is possible these principles would also apply to the PCV20-unique serotypes resulting in an underestimate of the burden.

Importantly, non-PCV13 serotypes included in UAD2 were associated with 523 (4.3%) cases in the current analysis, highlighting the remaining burden of serotypes not currently covered by a licensed conjugate vaccine. In particular, 400 cases (3.3%) were attributed to PCV20-unique serotypes, more than half of which were associated with serotypes not included in PCV15; proportions were generally higher in younger subjects across risk groups.

Clinical characteristics of subjects with PCV13-serotype and PCV20-unique serotype CAP were similar across many outcomes, including disease severity and hospitalization type and length of stay. This suggests that the invasive disease potential of PCV20-unique serotypes is similar to disease caused by PCV13 serotypes, against which there is a widely used vaccine [7]. The clinical burden of PCV20-unique serotypes is supported by previous studies identifying elevated prevalence as a global cause of IPD and related deaths, increased disease severity, and frequent antibiotic resistance in connection with these serotypes [7, 14, 31-36]. In the post-PCV era, 6 of the 7 PCV20-unique serotypes (8, 10A, 12F, 15B, 22F, and 33F) have emerged as prominent nonvaccine serotypes responsible for IPD worldwide [7, 14, 31, 32]. PCV20-unique serotypes are also responsible for a

substantial proportion of IPD-related deaths; one study in England and Wales reported that non-PCV13 serotypes including certain PCV20-unique serotypes (8, 11A, 15B, 15C, 22F, and 33F) were responsible for 73% to 92% of IPD-related deaths in children after PCV13 introduction [34].

Clinical manifestation of these serotypes can be particularly severe, as one study showed serotypes 10A, 22F, and 33F have a high likelihood of leading to meningitis compared with other serotypes [35]. Although meningitis was not assessed in the current study, almost half of subjects infected with PCV20-unique serotypes had very severe PSI (grade IV/V), highlighting the serious consequences of infection with these serotypes. Recent studies have shown that common nonvaccine serotypes identified among cases with antibiotic-resistant IPD included PCV20-unique serotypes such as 11A, 15B/15C, 22F, and 33F [33, 36]. Taken together, current and previous findings suggest that a PCV20 vaccine could further reduce pneumococcal disease severity and reduce mortality caused by PCV20-unique serotypes [34, 35]. Further, PCV20 could address growing concern over antibiotic resistance of *S pneumoniae* serotypes not currently covered by a vaccine licensed for use in pediatrics [33, 36]. Overall, the findings of this study, coupled with promising immunogenicity and safety findings from early PCV20 evaluation [15], suggest that PCV20 has the potential to prevent a sizeable proportion of existing adult CAP in the United States.

As noted for the previously published results, study limitations include most subjects having come from a single geographic area; however, the demographics of this area may be representative of the United States at large [1]. Another potential limitation of this study was the staggered start-up and the variable recruitment among sites and over time [3]. The study was also limited to hospitalized patients and did not assess the burden of CAP in the outpatient setting. No viral testing was included during the UAD2 assay, therefore another potential limitation is the lack of information on the interaction between bacteria and viruses in this setting. Additionally, determination of pneumococcal etiology in the current analysis is still limited by available laboratory methods as outlined above; however, the inclusion of 11 additional serotypes in the UAD2 assay [21] represents a critical leap in diagnostic capability for informing CAP etiology and potential for coverage by

higher-valent PCVs in development. Results of the current analysis are further strengthened by the large study size.

Conclusions

Findings from the current analysis highlight the remaining high burden of US adult pneumococcal CAP requiring hospitalization and suggest that higher-valent vaccines in development could prevent a substantial proportion of disease that is caused by PCV13 and non-PCV13 serotypes. Characterization of the distribution of these serotypes among different age and risk groups and associated disease may help inform vaccination decisions at both the individual and policy levels.

Accepted Manuscript

NOTES

Acknowledgments

This study was sponsored by Pfizer Inc. Editorial/medical writing support was provided by Judith Kandel, PhD, and Srividya Ramachandran, PhD, of ICON plc (North Wales, PA, USA), and was funded by Pfizer Inc. The authors would like to thank Dr. Mark van der Linden for his assistance with the Neufeld Quellung reaction.

Data Sharing Statement

Upon request, and subject to certain criteria, conditions and exceptions (see <https://www.pfizer.com/science/clinical-trials/trial-data-and-results> for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and/or EU or (2) in programs that have been terminated (ie, development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.

Funding

This work was supported by Pfizer Inc.

Conflicts of Interest

Raul Isturiz, Lindsay Grant, Sharon Gray, Ronika Alexander-Parrish, Qin Jiang, Luis Jodar, Paula Peyrani, Kimbal Ford, and Michael Pride are employees of Pfizer and may hold stock and/or stock options. Sharon Gray reports holding PFE stock and options, outside the submitted work. Wesley H. Self reports funding from Pfizer to their institution during the conduct of the study; Wesley H. Self has received funding for research and consulting from Merck & Co, Inc (was funded to participate in a pneumococcal pneumonia study); Wesley Self was funded to provide education sessions about pneumococcal pneumonia, outside the conduct of the study. Robert Sherwin and Gregory Volturo report no conflicts of interest. J. Scott Overcash reports that their institution was paid by Pfizer to conduct clinical trial, during the conduct of the study. Francis Counselman reports serving as a voluntary member of the Board of Directors of ECFMG/FAIMER, outside the conduct of the study. Julio Ramirez reports funding from Pfizer (payments made to the University of Louisville), during the conduct of the study. Luis Ostrosky-Zeichner has received funding for research (grant funds from

Pfizer to conduct this study and other clinical trials) during the conduct of the study, as well as honoraria for speaking and consulting from Pfizer (non-branded educational speaking), outside the submitted work. Richard Wunderink has received funding for consulting and is on a data safety monitoring committee for an unrelated Pfizer study (Clinical Evaluation Committee for unrelated antibiotic). Thomas File reports participation on Data Safety Monitoring Board for Shionogi (For Cefidercol study); Thomas file also reports being the Past President of Infectious Diseases Society of America, both outside the submitted work.

Accepted Manuscript

References

1. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology and mortality. *Clin Infect Dis*, **2017**; 65: 1806-1812.
2. Ferreira-Coimbra J, Sarda C, Rello J. Burden of community-acquired pneumonia and unmet clinical needs. *Adv Ther*, **2020**; 37: 1302-1318.
3. Isturiz RE, Ramirez J, Self WH, et al. Pneumococcal epidemiology among US adults hospitalized for community-acquired pneumonia. *Vaccine*, **2019**; 37: 3352-3361.
4. Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine *Streptococcus pneumoniae* serotypes in US adults aged ≥ 50 years with community-acquired pneumonia. *J Infect Dis*, **2013**; 208: 1813-1820.
5. Prevnar 13[®] (pneumococcal 13-valent conjugate vaccine [diphtheria CRM₁₉₇ protein]). Full Prescribing Information, Pfizer Inc, Collegeville, PA, 2017.
6. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Recomm Rep*, **2010**; 59: 258-261.
7. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. *Lancet Infect Dis*, **2015**; 15: 301-309.
8. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory

- Committee on Immunization Practices (ACIP). MMWR Recomm Rep, **2012**; 61: 816-819.
9. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, **2014**; 63: 822-825.
 10. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep, **2019**; 68: 1069-1075.
 11. Bonten MJ, Huijts SM, Bolkenbaas M, CAPITA coauthors. Vaccine against pneumococcal pneumonia in adults. N Engl J Med, **2015**; 373: 93.
 12. McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis, **2018**; 67: 1498-1506.
 13. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs): Trends by Serotype Group. Available at: <https://www.cdc.gov/abcs/reports-findings/survreports/spneu-types.html>. Accessed June 30, 2020.
 14. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of *Streptococcus pneumoniae* causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One, **2017**; 12: e0177113.
 15. Thompson A, Lamberth E, Severs J, et al. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine, **2019**; 37: 6201-6207.

16. Stacey HL, Rosen J, Peterson JT, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. *Hum Vaccin Immunother*, **2019**; 15: 530-539.
17. Wolff BJ, Bramley AM, Thurman KA, et al. Improved Detection of Respiratory Pathogens by Use of High-Quality Sputum with TaqMan Array Card Technology. *J Clin Microbiol*, **2017**; 55: 110-121.
18. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. *N Engl J Med*, **2015**; 373: 415-427.
19. Pride MW, Huijts SM, Wu K, et al. Validation of an immunodiagnostic assay for detection of 13 *Streptococcus pneumoniae* serotype-specific polysaccharides in human urine. *Clin Vaccine Immunol*, **2012**; 19: 1131-1141.
20. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine in prevention of adult pneumococcal pneumonia. *N Engl J Med*, **2015**; 372: 1114-1125.
21. Kalina WV, Souza V, Wu K, et al. Qualification and clinical validation of an immunodiagnostic assay for detecting 11 additional *S. pneumoniae* serotype-specific polysaccharides in human urine. *Clin Infect Dis*, **2020**; doi: 10.1093/cid/ciaa158 [Epub ahead of print].
22. Alexander R, Peyrani P, Ramirez J, et al. Rationale and methods of the study protocol: *Streptococcus pneumoniae* serotypes in adults 18 years and older with radiographically-confirmed community-acquired pneumonia (CAP). *Univ Louisville J Respir Infect*, **2017**; 1: 35-39.
23. Wunderink RG, Self WH, Anderson EJ, et al. Pneumococcal community-acquired pneumonia detected by serotype-specific urinary antigen detection assays. *Clin Infect Dis*, **2018**; 66: 1504-1510.

24. Lessa F, Spiller M. Effectiveness of PCV13 in adults hospitalized with pneumonia using centers for Medicare & Medicaid services data, 2014-2017. Presented at: Advisory Committee on Immunization Practices; February 28, 2019.
25. Gessner BD, Jiang Q, Van Werkhoven CH, et al. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. *Vaccine*, **2019**; 37: 5777-5787.
26. Kolditz M, Schmitt J, Pletz MW, Tesch F. Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of all-cause pneumonia in adults aged ≥ 60 years: a population-based, retrospective cohort study. *Clin Infect Dis*, **2019**; 68: 2117-2119.
27. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N Engl J Med*, **2015**; 372: 1114-1125.
28. Madhi SA, Klugman KP, Vaccine Trialist G. A role for *Streptococcus pneumoniae* in virus-associated pneumonia. *Nat Med*, **2004**; 10: 811-813.
29. Howard LM, Zhu Y, Griffin MR, et al. Nasopharyngeal Pneumococcal Density during Asymptomatic Respiratory Virus Infection and Risk for Subsequent Acute Respiratory Illness. *Emerg Infect Dis*, **2019**; 25: 2040-2047.
30. DeMuri GP, Gern JE, Eickhoff JC, Lynch SV, Wald ER. Dynamics of Bacterial Colonization With *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* During Symptomatic and Asymptomatic Viral Upper Respiratory Tract Infection. *Clin Infect Dis*, **2018**; 66: 1045-1053.
31. Hausdorff WP, Hanage WP. Interim results of an ecological experiment - conjugate vaccination against the pneumococcus and serotype replacement. *Hum Vaccin Immunother*, **2016**; 12: 358-374.

32. Cohen R, Cohen JF, Chalumeau M, Levy C. Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries. *Expert Rev Vaccines*, **2017**; 16: 625-640.
33. Metcalf BJ, Gertz RE, Jr., Gladstone RA, et al. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. *Clin Microbiol Infect*, **2016**; 22: e9-e29.
34. Oligbu G, Collins S, Sheppard CL, et al. Childhood deaths attributable to invasive pneumococcal disease in England and Wales, 2006-2014. *Clin Infect Dis*, **2017**; 65: 308-314.
35. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. *J Infect*, **2012**; 65: 17-24.
36. Tomczyk S, Lynfield R, Schaffner W, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. *Clin Infect Dis*, **2016**; 62: 1119-1125.

Accepted Manuscript

Figure Legends

Figure 1. *S pneumoniae* identification by diagnostic method among the 1482 positive samples.

Culture specimen types included blood (n=142), sputum (n=116), bronchoalveolar lavage (13), pleural fluid (3), or *other* (n=3). Circle areas are proportional to the number of total samples positive by the corresponding assays. UAD1=urinary antigen detection assay for PCV13 serotypes; UAD2=urinary antigen detection assay for 11 non-PCV13 serotypes.

Accepted Manuscript

1 **Tables**

2 **Table 1. Distribution of pneumococcal serotypes detected by culture or UAD1/UAD2 by age and risk group.**

	≥65 years of age, n (%) ^a			18–64 years of age, n (%) ^a				All Subjects, n (%) ^a
	All-Risk	High-Risk	At-Risk/Low-Risk	All-Risk	High-Risk	At-Risk	Low-Risk	
Subjects with radiographically confirmed CAP	6347 (100.0)	2773 (100.0)	3574 (100.0)	5708 (100.0)	1864 (100.0)	2976 (100.0)	868 (100.0)	12,055 (100.0)
Positive for <i>S pneumoniae</i> by UAD1/UAD2 or culture	530 (8.4)	215 (7.8)	315 (8.8)	604 (10.6)	193 (10.4)	331 (11.1)	80 (9.2)	1134 (9.4)
Not serotyped and UAD1/UAD2 negative	10 (0.2)	3 (0.1)	7 (0.2)	13 (0.2)	3 (0.2)	9 (0.3)	1 (0.1)	23 (0.2)
With serotype information	520 (8.2)	212 (7.7)	308 (8.6)	591 (10.4)	190 (10.2)	322 (10.8)	79 (9.1)	1111 (9.2)
UAD1/UAD2 serotypes ^b								
PCV13 serotypes	269 (4.2)	106 (3.8)	163 (4.6)	290 (5.1)	96 (5.2)	161 (5.4)	33 (3.8)	559 (4.6)
1	15 (0.2)	10 (0.4)	5 (0.1)	14 (0.3)	5 (0.3)	4 (0.1)	5 (0.6)	29 (0.2)
3	57 (0.9)	17 (0.6)	40 (1.1)	73 (1.3)	21 (1.1)	41 (1.4)	11 (1.3)	130 (1.1)
4	8 (0.1)	0 (0)	8 (0.2)	4 (0.1)	2 (0.1)	2 (0.1)	0 (0.0)	12 (1.0)
5	36 (0.6)	17 (0.6)	19 (0.5)	42 (0.7)	11 (0.6)	30 (1.0)	1 (0.1)	78 (0.7)
6A/6C ^c	33 (0.5)	12 (0.4)	21 (0.6)	21 (0.4)	4 (0.2)	15 (0.5)	2 (0.2)	54 (0.5)
6B	2 (0.0)	0 (0.0)	2 (0.1)	4 (0.1)	4 (0.2)	0 (0.0)	0 (0.0)	6 (0.1)
7F	24 (0.4)	6 (0.2)	18 (0.5)	30 (0.5)	8 (0.4)	18 (0.6)	4 (0.5)	54 (0.5)
9V	5 (0.1)	2 (0.1)	3 (0.1)	10 (0.2)	6 (0.3)	4 (0.1)	0 (0.0)	15 (0.1)

14	11 (0.2)	3 (0.1)	8 (0.2)	15 (0.3)	6 (0.3)	8 (0.3)	1 (0.1)	26 (0.2)
18C	6 (0.1)	4 (0.1)	2 (0.1)	16 (0.3)	7 (0.4)	9 (0.3)	0 (0.0)	22 (0.2)
19A	73 (1.2)	28 (1.0)	45 (1.3)	79 (1.4)	25 (1.3)	46 (1.6)	8 (0.9)	152 (1.3)
19F	10 (0.2)	7 (0.3)	3 (0.1)	9 (0.2)	5 (0.3)	3 (0.1)	1 (0.1)	19 (0.2)
23F	12 (0.2)	6 (0.2)	6 (0.2)	17 (0.3)	9 (0.5)	7 (0.2)	1 (0.1)	29 (0.2)
PCV20-unique serotypes	181 (2.9)	77 (2.8)	104 (2.9)	219 (3.8)	74 (4.0)	112 (3.8)	33 (3.8)	400 (3.3)
8	11 (0.2)	3 (0.1)	8 (0.2)	25 (0.4)	3 (0.2)	17 (0.6)	5 (0.6)	36 (0.3)
10A	24 (0.4)	11 (0.4)	13 (0.4)	27 (0.5)	6 (0.3)	18 (0.6)	3 (0.4)	51 (0.4)
11A	46 (0.7)	17 (0.6)	29 (0.8)	51 (0.9)	23 (1.2)	26 (0.9)	2 (0.2)	97 (0.8)
12F	13 (0.2)	5 (0.2)	8 (0.2)	21 (0.4)	9 (0.5)	11 (0.4)	1 (0.1)	34 (0.3)
15B/15C ^d	7 (0.1)	2 (0.1)	5 (0.1)	15 (0.3)	8 (0.4)	4 (0.1)	3 (0.4)	22 (0.2)
22F	59 (0.9)	28 (1.0)	31 (0.9)	67 (1.2)	21 (1.1)	31 (1.0)	15 (1.7)	126 (1.1)
33F	24 (0.4)	12 (0.4)	12 (0.3)	16 (0.3)	4 (0.2)	8 (0.3)	4 (0.5)	40 (0.3)
Non-PCV20 serotypes	54 (0.9)	19 (0.7)	35 (1.0)	69 (1.2)	15 (0.8)	41 (1.4)	13 (1.5)	123 (1.0)
2	3 (0.1)	3 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (0.0)
9N	23 (0.4)	8 (0.3)	15 (0.4)	37 (0.7)	9 (0.5)	23 (0.8)	5 (0.6)	60 (0.5)
17F	15 (0.2)	2 (0.1)	13 (0.4)	15 (0.3)	4 (0.2)	9 (0.3)	2 (0.2)	30 (0.3)
20	14 (0.2)	7 (0.3)	7 (0.2)	17 (0.3)	2 (0.1)	9 (0.3)	6 (0.7)	31 (0.3)

3 PCV13=13-valent pneumococcal conjugate vaccine; PCV20=20-valent pneumococcal conjugate vaccine; UAD1=urinary antigen detection assay for PCV13
 4 serotypes; UAD2=urinary antigen detection assay for 11 non-PCV13 serotypes.

5 ^aPercentages are calculated using the total number of subjects with radiographically confirmed CAP in each column as the denominator.

6 ^bSubjects could be positive for more than one serotype.

7 ^cSerotypes 6A and 6C are identified together as 6A/6C in the UAD1 assay; in contrast, in a previously published study [3], 6A and 6C were counted as distinct
8 serotypes.

9 ^dSerotypes 15B and 15C are identified together as 15B/15C in the UAD2 assay.

10 **Table 2. Demographics, risk status, and disease characteristics of subjects with radiographically**
 11 **confirmed CAP caused by PCV13 and PCV20-unique serotypes.**

	PCV13 Serotypes, ^a n (%)	PCV20-Unique Serotypes, ^a n (%)
Age, y ^b		
18–64	290 (51.9)	219 (54.8)
18–49	102 (18.2)	83 (20.8)
50–64	188 (33.6)	136 (34.0)
≥65	269 (48.1)	181 (45.3)
65–74	128 (22.9)	95 (23.8)
75–84	98 (17.5)	49 (12.3)
≥85	43 (7.7)	37 (9.3)
Sex ^b		
Female	273 (48.8)	200 (50.0)
Male	286 (51.2)	200 (50.0)
Race ^b		
White	452 (80.9)	319 (79.8)
Black	102 (18.2)	78 (19.5)
Asian	4 (0.7)	0 (0)
Other	1 (0.2)	3 (0.8)
Ethnicity ^c		
Hispanic/Latino	9 (1.6)	10 (2.5)
Non-Hispanic/Non-Latino	549 (98.4)	390 (97.5)
Risk Grouping ^b		
≥2 high-risk conditions with ≥1 at-risk condition(s)	44 (7.9)	34 (8.5)
≥2 high-risk conditions	9 (1.6)	5 (1.3)
≥1 high-risk condition(s) with ≥1 at-risk condition(s)	120 (21.5)	95 (23.8)
1 high-risk condition only	29 (5.2)	17 (4.3)
≥2 at-risk conditions	183 (32.7)	128 (32.0)
≥1 at-risk condition(s) only	113 (20.2)	72 (18.0)
No high-risk or at-risk conditions	61 (10.9)	49 (12.3)
PSI ^d		
Mean (SD)	90.7 (44.9)	85.9 (44.3)
Median	90	85
Minimum, maximum	0, 248	0, 217
PSI Grade ^d (Score)		
I	49 (8.9)	40 (10.3)
II (≤70)	103 (18.8)	90 (23.1)

III (71–90)	125 (22.8)	86 (22.1)
IV (91–130)	178 (32.4)	118 (30.3)
V (>130)	94 (17.1)	55 (14.1)
Inpatient hospitalization ^e		
General ward (medical/surgical unit)	425 (76.3)	293 (74.4)
Intensive care unit/Critical care unit	108 (19.4)	79 (20.1)
Pulmonary ward	6 (1.1)	6 (1.5)
Intermediate/Stepdown unit	10 (1.8)	11 (2.8)
Other	8 (1.4)	5 (1.3)
Inpatient hospitalization duration (d) ^{f,g}		
Mean (SD)	6.9 (4.4)	6.8 (4.5)
Median	6	6
Minimum, maximum	1, 29	1, 35
Hospitalization lasting ≥30 days ^{e,h}	0 (0)	3 (0.8)
Death within 30 days of enrollment ^b	48 (8.6)	26 (6.5)

12 CAP=community-acquired pneumonia; PCV13=13-valent pneumococcal conjugate vaccine;
 13 PCV20=20-valent pneumococcal conjugate vaccine; PSI=Pneumonia Severity Index.

14 ^aSubjects could be positive for both PCV13 serotypes and PCV20-unique serotypes.

15 ^bPCV13 serotypes, N=559; PCV20-unique serotypes, N=400.

16 ^cPCV13 serotypes, N=558; PCV20-unique serotypes, N=400.

17 ^dPCV13 serotypes, N=549; PCV20-unique serotypes, N=389.

18 ^ePCV13 serotypes, N=557; PCV20-unique serotypes, N=394.

19 ^fPCV13 serotypes, N=550; PCV20-unique serotypes, N=393.


20 ^gOnly subjects with hospital admission date and discharge date were included in the analysis.

21 “Ongoing” inpatient stays were not included in the analysis.

22 ^hSubjects with “ongoing” hospitalization status were included in the analysis.

23

Figure 1



Accepted